Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 9:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: EXPAREL 266 mg Clear all
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL, EXPAREL Admixed With Bupivacaine HCl vs. Bupivacaine HCl Administered as Combined Sciatic and Saphenous Nerve Blocks for Postsurgical Analgesia in Subjects Undergoing Lower Extremity Surgeries

NCT04518462
View directory record Official record
Conditions
Lower Extremity Surgery, Bunion, Metatarsophalangeal Fushion, Midfoot Fusion, Hindfoot Fushion, Total Ankle Arthroplasty
Interventions
Exparel, Bupivacaine Hydrochloride
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Phoenix, Arizona • Pasadena, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Sep 8, 2026, 9:42 AM EDT
Completed Not applicable Interventional Results available

Liposomal Bupivacaine Versus Standard Analgesia in Total Joint Arthroplasty (TJA)

NCT02197273
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip, Osteoarthritis, Shoulder
Interventions
Liposomal bupivacaine, Standard of care analgesia
Drug
Lead sponsor
OhioHealth
Other
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Sep 8, 2026, 9:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction

NCT05891613
View directory record Official record
Conditions
Breast Reduction
Interventions
Bupivacaine Hydrochloride, Liposomal Bupivacaine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 8, 2026, 9:42 AM EDT
Completed Phase 3 Interventional Results available

Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy

NCT05157841
View directory record Official record
Conditions
Bunionectomy, Hallux Valgus
Interventions
Bupivacaine liposome injectable suspension 266 mg, Bupivacaine HCl, Bupivacaine liposome injectable suspension 133 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
North Little Rock, Arkansas • Pasadena, California • Dayton, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Sep 8, 2026, 9:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Liposomal Bupivacaine on Post Operative Pain and Narcotic Use After Bariatric Surgery

NCT03196505
View directory record Official record
Conditions
Bariatric Surgery Candidate, Pain, Postoperative
Interventions
Exparel 266 MG Per 20 ML Injection, Bupivacaine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 8, 2026, 9:42 AM EDT
Terminated Phase 4 Interventional Results available

A Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy

NCT02058290
View directory record Official record
Conditions
Bowel Obstruction
Interventions
IV morphine sulfate or Sponsor-approved equivalent, EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Miami, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 8, 2026, 9:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery

NCT04117074
View directory record Official record
Conditions
Surgery, Analgesia
Interventions
Liposomal bupivacaine, Thoracic epidural analgesia (bupivacaine)
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 8, 2026, 9:42 AM EDT
Not yet recruiting Not applicable Interventional

Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1

NCT07254650
View directory record Official record
Conditions
Lung Cancer (Diagnosis)
Interventions
Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block, Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block, Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 8, 2026, 9:42 AM EDT
Terminated Phase 4 Interventional Results available

Exparel vs. Standard Bupivicaine for Abdominoplasty

NCT01853176
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Liposomal Injection Bupivacaine (Exparel), Standard bupivicaine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2014 · Synced Sep 8, 2026, 9:42 AM EDT
Completed Phase 4 Interventional Results available

Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair

NCT02128646
View directory record Official record
Conditions
Pain
Interventions
EXPAREL, Ketorolac, laparoscopic abdominal hernia repair, an open surgery for abdominal hernia repair
Drug · Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 8, 2026, 9:42 AM EDT
Terminated Phase 4 Interventional Results available

Phase 4, Controlled Study in Adult Subjects Undergoing Primary, 1-2 Level, Open Lumbar Spinal Fusion Surgery

NCT03015961
View directory record Official record
Conditions
Postoperative Pain Management
Interventions
EXPAREL and bupivacaine HCl, Bupivacaine HCl
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
15
States / cities
Gilbert, Arizona • Phoenix, Arizona • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Sep 8, 2026, 9:42 AM EDT
Completed Phase 4 Interventional Results available

EXPAREL Infiltrated Into the TAP for Postoperative Analgesia in Unilateral Abdominal Hernia Repair

NCT01801124
View directory record Official record
Conditions
Hernia
Interventions
EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2021 · Synced Sep 8, 2026, 9:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pain Control in Colorectal Surgery: Liposomal Bupivacaine Block Versus Intravenous Lidociane

NCT04005859
View directory record Official record
Conditions
Colorectal Disorders
Interventions
Exparel, IV Lidocaine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 8, 2026, 9:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections

NCT03176459
View directory record Official record
Conditions
C-Section, Pain Management
Interventions
Exparel + Bupivacaine, Bupivacaine
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
12
States / cities
Loma Linda, California • Stanford, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 8, 2026, 9:42 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty

NCT01683071
View directory record Official record
Conditions
Postoperative Pain
Interventions
Placebo, EXPAREL 67 mg, EXPAREL 133 mg, EXPAREL 266 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
30
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 8, 2026, 9:42 AM EDT
Recruiting Phase 3 Interventional

Efficacy of EXPAREL vs. Bupivacaine

NCT07212114
View directory record Official record
Conditions
Total Ankle Arthroplasty, Postsurgical Analgesia
Interventions
EXPAREL, 0.25% bupivacaine (HCl): 50 ml, 0.25% bupivacaine (HCl): 30 ml
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 8, 2026, 9:42 AM EDT
Completed Phase 4 Interventional Results available

Local Infiltration Analgesia With and Without EXPAREL Following Total Knee Arthroplasty

NCT02713490
View directory record Official record
Conditions
Pain
Interventions
EXPAREL, Bupivacaine
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
17
States / cities
Fremont, California • Loma Linda, California • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 8, 2026, 9:42 AM EDT
Not listed Not applicable Interventional

Early Post-Operative Pain Control Following Wrist Operations

NCT02052180
View directory record Official record
Conditions
Pain
Interventions
Exparel, Marcaine (Control)
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Sep 8, 2026, 9:42 AM EDT
Completed Phase 3 Interventional Results available

Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy

NCT01802411
View directory record Official record
Conditions
Posterolateral Thoracotomy, Postoperative Pain
Interventions
EXPAREL 266 mg, Placebo
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Miami, Florida • Shreveport, Louisiana • Fargo, North Dakota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 8, 2026, 9:42 AM EDT
Completed Phase 4 Interventional Results available

A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B504

NCT01509807
View directory record Official record
Conditions
Retraction of Colostomy
Interventions
IV morphine sulfate or Sponsor-approved equivalent, EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
Tucson, Arizona • Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 6, 2014 · Synced Sep 8, 2026, 9:42 AM EDT
Suspended Phase 4 Interventional

Liposomal Bupivacaine in One-level Instrumented Posterior Spinal Fusion

NCT03745040
View directory record Official record
Conditions
Lumbar Spinal Stenosis, Lumbar Disc Herniation, Lumbar Disc Disease, Lumbar Spondylolisthesis
Interventions
Liposomal bupivacaine
Drug
Lead sponsor
Allina Health System
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 8, 2026, 9:42 AM EDT
Terminated Phase 4 Interventional Results available

Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section

NCT02353754
View directory record Official record
Conditions
Pain
Interventions
Intrathecal morphine injection, EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
5
States / cities
Port Saint Lucie, Florida • Minneapolis, Minnesota • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 8, 2026, 9:42 AM EDT
Completed Phase 4 Interventional Results available

Pectoralis and Serratus Muscle Blocks

NCT03743194
View directory record Official record
Conditions
Post Operative Pain Control
Interventions
Exparel 266 MG Per 20 ML Injection, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 8, 2026, 9:42 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Efficacy of Single Injection Femoral Nerve Block With Liposomal Bupivacaine for Total Knee Arthroplasty

NCT01977339
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Liposome Bupivacaine, Bupivacaine
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 8, 2026, 9:42 AM EDT